Hims & Hers Health has announced a new partnership with Novo Nordisk, set to launch a bundled offering that includes Wegovy, the widely-used weight-loss medication, along with a full telehealth membership subscription.
This collaboration will provide customers access to Wegovy at all dosage levels, combined with a Hims & Hers membership that features round-the-clock care, ongoing clinical assistance, and nutritional advice, according to the company’s statement.
“Partnering with Novo Nordisk, recognized for its innovative contributions to clinical medicine and a robust portfolio of medications, is a thrilling development for us,” stated Hims & Hers CEO Andrew Dudum. “Together, we envision a future shaped by consumer-centered healthcare, and this initiative represents a significant step in that direction.”
The announcement prompted a notable reaction in the stock market, with Hims & Hers shares soaring by 25% in response.
The new bundle will be priced starting at $599 per month. Additionally, it will integrate NovoNordisk’s NovoCare Pharmacy, a direct-to-consumer online pharmacy specifically designed for cash-paying Wegovy users, which launched last month.
NOVO NORDISK CUTS WEGOVY PRICES IN HALF FOR CASH-PAYING CONSUMERS
The partnership is set to roll out the Wegovy package on the Hims & Hers platform later this week, offering all dosage strengths of Wegovy in a premium self-pay pen.
GET Finance Newso BUSINESS ON THE GO BY CLICKING HERE
Furthermore, Hims & Hers stated that they are collaborating with Novo Nordisk to create a strategic plan that aligns the Danish pharmaceutical company’s groundbreaking treatments with the telehealth service’s capacity to broaden access to quality healthcare solutions.
In similar developments, two other telehealth entities, Ro and Life MD, also revealed partnerships with Novo Nordisk on the same day, signaling a wider trend of integrating NovoCare Pharmacy into their services while providing access to Wegovy.
OZEMPIC, WEGOVY AMONG DRUGS SUBJECT TO MEDICARE PRICE CONTROLS
Wegovy has gained notable traction in recent years as one of several GLP-1 medications favored for weight management, sharing the spotlight with Novo’s Ozempic and Eli Lilly’s Zepbound and Mounjaro.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| HIMS | HIMS & HERS HEALTH | 34.02 | +5.54 | +19.44% |
| NVO | NOVO NORDISK A/S | 62.62 | +0.54 | +0.87% |
